Introduction
There is increasing focus on pharmaceutical expenditure globally [1] , driven by factors including changing demographics and the continued launch of new premium priced medicines [1] [2] [3] [4] [5] [6] [7] . This has stimulated a number of initiatives surrounding generics, with European countries learning from each other as they continually search for additional measures to further enhance prescribing effi ciency [1, 3, 4, 6, 7] . Initiatives include measures to enhance the utilisation of generics versus originators and patent protected products in the class or related class, as well as measures to obtain low prices for generics [1, 3, 4, [6] [7] [8] . This includes generic clopidogrel, with global sales of the originator at US$9.8 billon in 2009 and US$9.7 billion in 2010 [9, 10] . However, there have been concerns with different salts and indications between the originator and early generic clopidogrel formulations, which could reduce potential health authority and health insurance agency savings from the availability of generic clopidogrel. In addition in the US, the originator manufacturer also instigated 25 ; Corrine Zara 26 various generic clopidogrel preparations through its centralised procedure [11, 13, 14] . This included more than 20 generic clopidogrel products, which contained the besilate and hydrogen sulphate salts, of which eight were approved for both indications, i.e. both secondary prevention and ACS indications [15] . However, in the UK for instance, initial generics typically only included the secondary prevention indication in their submissions [15, 16] .
Health authority or health insurance agencies faced similar issues to drug licensing authorities when considering reimbursement and/or recommending the prescribing of generic clopidogrel versus the originator potentially impacting on outcomes. These included whether changing the salt would alter the rate of absorption, toxicity and stability of the active drug. In addition, effi cacy questions were raised by the fact that bioequivalence studies measured only the parent compound or inactive metabolite rather than the low and transient concentrations of the active metabolite, present only briefl y after dosing, as well as possible concerns with inter-patient variability [17] [18] [19] [20] [21] [22] . There have also been concerns among some authorities that any putative interaction between clopidogrel and proton pump inhibitors will be less well known initially for the generic salts. These concerns were in addition to patent issues in each European country, the latter leading to widely different dates when generics become available for prescribing [3, 4] . Additionally, there have been issues regarding the functional integrity of CYP2C19 in patients as this could potentially affect the availability of the clopidogrel and hence outcomes in practice [23, 24] . As such, personalised medicine using tailored individualised antiplatelet treatment based on pharmacogenetic testing could be helpful in identifying which patients should be treated with clopidogrel and which with newer drugs such as prasugrel and ticagrelor. However, other studies have questioned this [25] [26] [27] [28] [29] . In any event, this should not impact on the debate of whether generic or originator clopidogrel should be prescribed. Of potential greater importance is the widely different timescales that currently exists among European countries when authorising reimbursement for generics [13, 30] .
The situation for health authorities and health insurance agencies was further complicated by the EMA recall in March 2010 of clopidogrel besylate produced by Glochem Industry Ltd's manufacturing facility in India [31] [32] [33] [34] . The medicines concerned included Clopidogrel 1 A Pharma, Clopidogrel Acino, Clopidogrel Acino Pharma, Clopidogrel Acino Pharma GmbH, Clopidogrel Hexal, Clopidogrel Ratiopharm, Clopidogrel Ratiopharm GmbH and Clopidogrel Sandoz. The marketing authorisation holder of all these products was Acino Pharma GmbH [31] [32] [33] [34] , which held the market authorisation for the majority of early generics formulations. However, Acino and other companies have been able to source generic clopidogrel from other companies to overcome possible supply problems, with multiple companies and formulations now typically available across Europe. The originator manufacturer tried to take advantage of these recalls through pointing out the known quality of Plavix [35] . The impact of this approach though was reduced in reality by EMA approval of a number of generic clopidogrel formulations from different manufacturers. In addition, European health authorities and health insurance companies are continually seeking ways to fund new premium priced drugs and increased drug volumes from ageing populations within fi nite resources through encouraging greater generics utilisation, Table 1 below as well as references 1 and 36 contain examples of different authority approaches across Europe to enhance generics utilisation with similar approaches among managed care organisations in the US [1-4, 5-8, 36] .
Consequently, the principal objective of this paper is to document health authority and health insurance agency responses to take advantage of the early availability of generic clopidogrel products. Secondly, to assess potential reasons preventing health 
Method
We fi rst performed a literature review of English language papers in PubMed, MEDLINE and Embase between 2005 and April 2011 using the keywords 'generic clopidogrel'. But because this resulted in only a limited number of publications, e.g. only seven relevant English language papers were cited in PubMed, the literature search was supplemented by additional information, papers and web-based articles known to the many co-authors from health authorities, health insurance agencies and their advisers from across Australia, Europe and the Middle East regarding generic clopidogrel. This information was subsequently re-confi rmed with each co-author by the lead co-author Dr Brian Godman to ensure the accuracy of the data provided, hence its robustness. This is an accepted technique where there is limited information publically available to achieve study aims [2-4, 6, 7, 37-42] .
No attempt was made to review the quality of the published studies using the methodology of the Cochrane Collaboration [43] in view of the paucity of peer-reviewed published studies. The fi ndings were again validated with pertinent co-authors to ensure accuracy. Data from administrative databases included reimbursed expenditure/defi ned daily dose (DDD)-with DDDs defi ned as 'the average maintenance dose of the drug when used on its major indication in adults' [44] -for both the originator and generics. This approach has been successfully used in previous publications when reviewing the impact of ongoing reforms to reduce generic prices versus originators to enhance future prescribing effi ciency in Europe [2-4, 6, 7, 37-40] . The countries reviewed were selected based on their different geographies, fi nancial base for the healthcare system (taxation or insurance based) and population size to enable comprehensive comparisons of payer activities as well as reimbursed prices to provide examples to others. In addition in some countries, generic clopidogrel has only recently been reimbursed, see Table 2 .
The demand-side measures initiated in each selected country to enhance the utilisation of generic clopidogrel have been taken from published sources supplemented with additional information from the co-authors. The latter approach providing 
Country
Health authority and health insurance responses to enhance the prescribing and dispensing of generic clopidogrel where possible
Abu Dhabi
Generic clopidogrel was reimbursed in January 2011. Demand-side measures to increase the utilisation of generic clopidogrel include compulsory INN prescribing (Enforcement). However, community pharmacists are currently fully reimbursed for any formulation dispensed (originator or generic) and patients do not have to cover the additional costs themselves for a more expensive product than the cheapest molecule, i.e. no reference pricing for the molecule unlike most European countries. These issues are now being addressed through the instigation of pharmacy benefi t management and other activities. • The authorities wrote a public letter in response to the Austrian Society of Cardiology, who had suggested to physicians that they should not prescribe generic clopidogrel as it may not work in all indications, especially the stent-indication, due to different salts. The letter from the authorities stated that there is no difference in effi cacy or safety between the various salts, and even if there are some patent issues preventing all indications being listed, this is not due to safety and effi cacy issues. This was followed by a pharmacological publication in 2010 elaborating why there is no reason for concern, which was subsequently published through joint activities with health insurance agencies in several medical and pharmaceutical papers as well as in all nine federalregional health insurance newspapers. The Austrian Society of Cardiology subsequently indicated they better understood the salt-issue, and the article helped to allay their fears.
Austria Licensing authorities -activities

Health Insurance activities
Activities to enhance generics prescribing include:
• Education -Quarterly publications to health insurance physicians highlighting the current cheapest branded generic for the molecule. In addition, new IT systems available also highlighting cheapest generic.
• Engineering -Listing generic clopidogrel in the 'green box', i.e. no restrictions versus 'yellow' box for Plavix.
(Continued) • Economics -Financial incentives (limited) for prescribing generics; reprimands for continued excessive prescribing costs versus colleagues. There have been no real issues from a health insurance perspective arising from the withdrawal of some formulations of generic clopidogrel from the market place.
Croatia
Generic clopidogrel is reimbursed and prescribed for secondary prevention (post bypass surgery) and for patients with Acute Coronary Syndrome (ACS), with access to patients' history to check prescribing if needed.
The fi rst generic clopidogrel was reimbursed in November 2006. There are currently fi ve generics manufacturers (branded generics) with Plavix now on the reimbursement list following price cuts by Sanofi -Aventis.
Demand-side measures include:
• Economics -Reference pricing for the molecule, with the Croatian Institute for Health Insurance only covering cost of the lowest priced generic, with patients covering the additional costs for a more expensive product.
Denmark
There is currently substitution of originator clopidogrel in Denmark to enhance the prescribing and dispensing of generic clopidogrel, with a number of generic versions now available (fi rst one reimbursed in August 2009).
There are currently no reported issues to adversely affect the dispensing of generic clopidogrel.
England
Primary Care Trusts in England typically took a pragmatic approach to the availability of generic clopidogrel in view of current sales and envisaged savings. This was typically endorsed by both specialists and General Practitioners despite initial concerns by the National Prescribing Centre.
• Education -Benchmarking, formularies, IT support systems and academic detailing (where necessary) to continue high INN prescribing rates including clopidogrel.
• Engineering -Prescribing targets where necessary to enhance the prescribing of generic clopidogrel.
• Economics -Financial incentives (where necessary) to enhance the prescribing of generic clopidogrel.
Estonia
Generic clopidogrel was reimbursed on 1 January 2010, although generic versions were available before this helping to drive down the price of the originator.
Demand-side measures to enhance generics prescribing include:
• Education -Health Insurance Fund provides information to physicians to enhance their prescribing effi ciency where concerns.
• Economics -Patients have to cover the costs themselves for a more expensive product than the reference priced molecule.
• Enforcement -Compulsory INN prescribing in Estonia. Physicians can prescribe the originator product if they believe it is medically relevant; however, they have to provide an explanation in the medical records (diffi cult for generic clopidogrel). • Other measures (CAPI) involving clopidogrel to enhance overall prescribing effi ciency include a target prescribing indicator that 85% of patients treated with platelet aggregation inhibitors (all drugs included in class ATC B01 AC + pravadual) should be treated with low dose aspirin (Engineering).
(Continued) 
Finland
The fi rst generic clopidogrel received reimbursement status on 1st December 2009. There were no supply issues when a number of generic versions were withdrawn from the market as additional generic versions became available to cover the shortfall. Consequently, no additional activities from the Social Health Insurance to re-assure physicians and patients regarding generic clopidogrel.
Demand-side measures:
• Economics and Enforcement -There appeared to be no concerns with substitution with the cheapest product mandatory unless forbidden by the physician or patients prepared to pay the additional costs for a more expensive product themselves (Economics) -not generally seen in practice.
Germany
Germany was one of the fi rst Western European countries where generic clopidogrel was launched and reimbursed. The differences in the salt and indications between the generics and the originator were typically dismissed by physicians due to fi nancial incentives/penalties in the system despite the originator manufacturer trying to make a big issue of both issues.
Demand-side measures to enhance the prescribing and dispensing of generic clopidogrel:
• Education -Letter to physicians, articles in magazines, encouraging the prescribing of generic clopidogrel.
• Engineering -Rebate negotiations between manufacturers and sickness funds.
• Economic -Budgets linked with fi nancial incentives and penalties related to prescribing and budget targets.
Lithuania
Generic clopidogrel was reimbursed in the last quarter of 2009.
Demand-side measures include:
• Economics -Community pharmacists are obliged to stock the cheapest generics with fi nancial penalties if they do not comply.
• Enforcement -INN prescribing mandatory unless physicians receive prior approval from the Hospital or Polyclinic Therapeutic Committee (does not apply to generic clopidogrel). The originator has reduced its prices to compete.
Norway
Generic clopidogrel (Clopidogrel Mylan) was fi rst accepted for reimbursement 1 December 2009, with sales from January 2010 as the Norwegian Medicines Agency (Statens legemiddelverk, NoMA) considered the different salts and indications substitutable. However, following activities by the originator company challenging the patent and indications, generic clopidogrel was removed from the reimbursement list from 1 October 2010.
Since then, generic clopidogrel (Clopidogrel Actavis) has received market authorisation with the reimbursed indication approved, and accepted for reimbursement from 1 March 2011.
Poland
The fi rst generic clopidogrel was launched in 2008, with no issues since then. Currently six generics manufacturers make their formulations available (June 2011). Prescribing of generic clopidogrel is enhanced by reference pricing for the molecule, with patients covering the additional costs for a more expensive product (Economics) in addition to a 50% co-payment).
Portugal
The fi rst generic clopidogrel was approved by Infarmed in April 2009 and reimbursed in December 2009 (69% reimbursement rate). Clopidogrel was subsequently introduced into the Portuguese reference price system (internal reference price) in January 2010.
Certain formulations of generic Clopidogrel were withdrawn in 2010 due to concerns with manufacturing (March 2010 
Scotland
In Scotland, there was a pragmatic approach with Area Drugs and Therapeutics Committees recommending prescribing of generic clopidogrel rather than Plavix.
Again, the prescribing of generic clopidogrel is enhanced by high INN prescribing rates in Scotland (Education) coupled with regular monitoring of prescribing/academic detailing (Education) and fi nancial incentives for General Practitioners (Economics).
(Continued) The only current recommendations regarding generic clopidogrel are concerning specifi c salts to dispense in nursing homes, when packs are broken down for unit dispensing, as there can be stability concerns.
Serbia
The fi rst clopidogrel was reimbursed in August 2006, with no real issues regarding different salts or indications.
Recent measures to lower the price of generics in Serbia include the originator and generic drugs must now have the same price to be reimbursed, i.e. no opportunity for patients to pay an additional co-payment for a more expensive product. There are currently fi ve generic clopidogrel versions in Serbia (August 2011), all manufactured by the domestic generics industry except for one product (Actavis).
Slovenia
There has been mixed availability of generic clopidogrel in Slovenia. Generic clopidogrel was available between June 2006 and June 2008. Subsequently, it was removed from the market because of patent problems following a challenge by the originator manufacturer. However, since May 2010 generic clopidogrel has again been available and reimbursed.
Activities to enhance generics prescribing include additional co-payments for more expensive compounds than the reference product (Economics). Physician can write 'Do not substitute', but this is not frequently used.
Spain (Catalonia)
Generic clopidogrel was fi rst approved in Spain in September 2009 and fi rst reimbursed in April 2010. Measures to lower the price of generics include the reference price system, which establishes a maximum reimbursement price with no possibility for the patient to cover the additional costs themselves for a more expensive product. For products dispensed by INN name, the pharmacy should dispense the cheapest product (preferably generics).
However, originator manufacturers of new molecules included in the reference price system have a period of two years to decrease their prices to the reference price, decreasing each year by 50% of the difference between the originator and the reference price. Consequently, these products can maintain a higher price for a period of time, with the resultant price difference sometimes substantial as seen with clopidogrel.
Activities to enhance effi ciencies from the availability of generic clopidogrel are compounded in Catalonia by hospital specialists continuing to prescribe the originator and disagreeing that primary care physicians can change the prescription. This is due to ongoing concerns regarding the effectiveness and safety of the generics, enhanced by the withdrawal of some generic compounds and the lack of all indications among the generics -especially the ACS indications.
Activities to address this include:
• Education -Information and other activities by the Catalan Drugs Information. Center (Centre d'Informació de Medicaments de Catalunya) to address any misinformation regarding generic clopidogrel as well as highlighting the cost differential between the originator and generics.
• Engineering -Asking the Health Minister to address the anomaly with substitution where there are different indications between approved generics and the originator. In addition, encouraging systematic substitution in ambulatory care with physician agreement coupled with patient information if needed to address any concerns regarding the effectiveness and/or safety of the generic versus the originator.
Sweden
The Swedish Medical Products Agency (Läkemedelsverket) decided that the originator could be substituted ahead of its availability despite different salts and indications from the originator. Alongside this, there appeared to be no real issues with the withdrawal of certain formulations of generic clopidogrel, e.g. Stockholm County Council's expert group discussed the withdrawal of certain formulations; however, no action was taken as none of the formulations withdrawn were recommended in the 'Wise List'.
Grepid (Orifarm Generics) was the fi rst generic clopidogrel to be reimbursed in Sweden (November 2009), with the generics from four companies becoming available the following month.
Demand-side activities:
• Education -Making sure recommended generic formulations are included within current County Council (Regional) formularies.
• Enforcement -Mandatory substitution in the pharmacy unless concerns or the patient is prepared to pay the difference for a more expensive product (rare in practice).
most data in view of, as stated, limited available information in the public domain. Demand-side activities were again checked with pertinent co-authors to ensure the accuracy of the information provided. The various demand-side measures were subsequently collated using the 4E methodology,
i.e. education, engineering, economics and enforcement, to simplify comparisons between countries, see Table 1 . This approach has been successfully used in other settings to compare and contrast the infl uence of different demand-side interventions in practice [3, 4, 6, [38] [39] [40] .
Results
Most health authorities and insurers have adopted a pragmatic approach towards differences in the salt and indications between the generic and the originator to enhance the prescribing of generic clopidogrel, see Table 2 ; with examples of pragmatic approaches documented in Table 3 . However, this has not always been possible. For example, activities in Norway, Portugal and Slovenia have resulted in all or some versions of generic clopidogrel being removed from the market place for a period of time, see Table 2 . 
Northern Ireland
• Stated that 'As all clopidogrel preparations are deemed to be bioequivalent, the Northern Ireland Medicines Management Forum recommends that prescribers should continue to prescribe generically for all indications in both primary and secondary care'.
• This arose because the authorities believed that since EU and UK licensing authorities were satisfi ed that available generic clopidogrel products are bioequivalent to the reference product, generic clopidogrel products should not differ signifi cantly in terms of effi cacy and safety from the originator. As a result, originator and generic clopidogrel preparations should be considered therapeutically equivalent.
• Alongside this, following instigation of recent supply side reforms in the UK leading to lower prices for generics, i.e. generic clopidogrel was already over 90% below originator prices in December 2010, the authorities believed National Health Service healthcare professionals have 'a duty to make the best use of public resources; cost as well as clinical suitability and product quality must be considered when choosing appropriate preparations'.
Scotland
The advice from one of the leading health boards in Scotland, the Greater Glasgow Area Drugs and Therapeutics Committee, was that since bioequivalence had been proven, the risks from prescribing as yet unlicensed indications were 'negligible', and physicians should go ahead and prescribe generic clopidogrel.
Sweden
The Medicines Product Agency, Läkemedelsverket, decided ahead of generics availability that the originator could be substituted with the different generic salts, with compulsory generics substitution already in place in Sweden apart from a minority of situations. 
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There has also been extensive education of physicians in some European countries to allay their fears about prescribing generic clopidogrel with different salts and indications, see Table 2 . As a result, utilisation of generic clopidogrel has been enhanced thereby helping health authorities and health insurance agencies gain savings from the early availability of generic clopidogrel given the global expenditure on Plavix pre-patent loss [9, 10] .
The various measures instigated among countries to obtain low price of generics [2, 4] has already resulted in appreciable price reductions in some countries, see Table 4 . However, this was not universal with a 20-fold difference in reimbursed prices existing between countries in April to July 2011, see Table 4 .
Conclusion
Health authorities and health insurance agencies have typically adopted a pragmatic approach to enhance the prescribing and dispensing of generic clopidogrel once available. As a result, valuable resources have been released from the early availability of generic clopidogrel. This is despite different salts and more limited indications initially versus the originator, coupled with the withdrawal of some formulations of generic clopidogrel from the market place due to manufacturing concerns.
Activities undertaken by health authorities and health insurance agencies to enhance the prescribing of generic clopidogrel, see Table 2 , mirror those undertaken for other generics [2-4, 6, 7, 37-40] . They also included extensive education among key stakeholder groups in some countries to enable health authorities and health insurance agencies to fully realise the fi nancial benefi ts from the early availability of generic clopidogrel. However, activities in some countries have not always been possible following successful challenges to the availability of generic clopidogrel, which led to the removal of all or some formulations for a period of time, see Table 2 .
It may well be in the long term that compliance is a greater issue to maximise outcomes from clopidogrel than any perceived differences in bioavailability between formulations, mirroring the situation with other cardiovascular drugs [51] . Consequently, some of the resources released from the availability of generic clopidogrel could be used to address this issue to maximise the health gain from clopidogrel alone or in combination with aspirin among pertinent patients.
There is considerable variation in reimbursed prices for generic clopidogrel, and versus the originator, see Table 4 , mirroring the fi ndings in other studies [2, 3, 4, 6] . Again the size of the country's population does not appear to be responsible for these differences, confi rming previous publications [37] . Price reductions appear to be determined largely by ongoing policies to enhance generics utilisation [1] [2] [3] [4] 52] . It is likely though that in time reimbursed prices for clopidogrel will converge, driven largely by countries striving to release further resources from the increasing availability of generics [53] . This will be researched in future studies alongside the impact of the various policies in each country to enhance the prescribing of generic clopidogrel versus the originator, see Table 2 .
In conclusion, payers across Europe are learning from each other how best to take full advantage of the early availability of generics, even when there are different salts and indications, to maximise the use of available resources. This will continue. However, as we have seen this is not always possible. We believe pharmaceutical companies should accept generics availability to enable continued funding of new premium priced products, and not try to delay their introduction through challenging reimbursement decisions. The alternative, as resource pressures continue growing, is limited or no funding for new drugs, which is not in the future interests of all key stakeholder groups [1-4, 8, 54] .
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